Listen

Press releases

Receive e-mail alerts

Interne link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
mei 31, 2017 om 11:00 AM UTC
Interne link ProQR Announces Results for the First Quarter of 2017
mei 17, 2017 om 11:00 AM UTC
Interne link ProQR remembers co-founder Henri Termeer after his unexpected passing
mei 15, 2017 om 11:00 AM UTC
Interne link ProQR Announces R&D Day in New York on June 15
mei 09, 2017 om 11:00 AM UTC
Interne link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome
mei 01, 2017 om 11:00 AM UTC
Interne link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
april 27, 2017 om 11:00 AM UTC
Interne link ProQR to Present at the Deutsche Bank Health Care Conference
april 20, 2017 om 11:00 AM UTC
Interne link ProQR Announces Annual Meeting of Shareholders
april 10, 2017 om 11:00 AM UTC
Interne link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
april 03, 2017 om 11:00 AM UTC
Interne link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
maart 27, 2017 om 11:00 AM UTC
Interne link ProQR to Present at Two Upcoming Investor Conferences in March
maart 01, 2017 om 12:00 PM UTC
Interne link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
februari 28, 2017 om 12:00 PM UTC
Interne link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
februari 27, 2017 om 12:00 PM UTC
Interne link ProQR to Present at the LEERINK Partners Global Healthcare Conference
februari 07, 2017 om 12:00 PM UTC
Interne link ProQR Therapeutics Announces Results for the Third Quarter of 2014
november 24, 2014 om 12:00 PM UTC
Interne link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
september 23, 2014 om 05:37 PM UTC
Interne link ProQR Announces Pricing of Initial Public Offering
september 18, 2014 om 12:07 PM UTC

Press releases

Interne link ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

Interne link ProQR Announces Results for the First Quarter of 2017

Interne link ProQR remembers co-founder Henri Termeer after his unexpected passing

Interne link ProQR Announces R&D Day in New York on June 15

Interne link ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

Interne link ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

Interne link ProQR to Present at the Deutsche Bank Health Care Conference

Interne link ProQR Announces Annual Meeting of Shareholders

Interne link ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU

Interne link ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

Interne link ProQR to Present at Two Upcoming Investor Conferences in March

Interne link ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update

Interne link On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day

Interne link ProQR to Present at the LEERINK Partners Global Healthcare Conference

Interne link ProQR Therapeutics Announces Results for the Third Quarter of 2014

Interne link ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Interne link ProQR Announces Pricing of Initial Public Offering